

Group II: Claims 62-70, 79-82 and 85, drawn to a treatment combination for neoplasm lymphoid cells comprising a therapeutically effective amount of a compound of formula I and raising intracellular concentrations of cAMP.

Further, the Examiner has indicated that an election of species is required. In particular, if group I or II is elected, Applicants are required to elect one specific chemical compound from those recited in pending claims 39-42, 44-49 and 62-70, and one differentiation inducing agent from those recited in pending claims 75-78, 81 and 82. If group II is elected, Applicants are required to elect one agent effective in raising intracellular concentrations of cAMP.

ELECTION

Applicants elect group I, drawn to claims 39-42, 44-49, 75-78 and 84 drawn to a method of treating neoplasms of lymphoid cells in a mammal. Further, Applicants elect roflumilast as the specific chemical compound, and all trans retinoic acid as the specific differentiation inducing agent.


CONCLUSION

If the Examiner has any questions or wishes to discuss this matter, the Examiner is welcomed to telephone the undersigned attorney.

Respectfully submitted,

THE NATH LAW GROUP

Date: February 28, 2008
THE NATH LAW GROUP
112 South West Street
Alexandria, VA 22314
Telephone: (703) 548-6284
Facsimile: (703) 683-8396



Gary M. Nath
Reg. No. 26,965
Sheldon M. McGee
Reg. No. 50,454
Customer No. 34375

SMM/few\RRR.doc